Mounjaro (tirzepatide), developed by Eli Lilly and Company, has been widely prescribed for managing Type 2 diabetes and weight loss. While its clinical outcomes have impressed many healthcare providers, a growing number of patients have reported serious gastrointestinal side effects most notably a condition known as gastroparesis, or stomach paralysis.
For attorneys and law firms handling pharmaceutical litigation, this is a rapidly evolving area of law. Cases involving Mounjaro stomach paralysis require a solid understanding of the medical evidence, a clear grasp of the legal theories at play, and access to organized, attorney-ready medical records. This guide is written specifically for legal professionals navigating these complex claims.
Table of Contents
What Is Mounjaro and How Does It Work?
Mounjaro is the brand name for tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It was approved by the U.S. Food and Drug Administration (FDA) in May 2022 for the treatment of Type 2 diabetes in adults.
Unlike earlier GLP-1 drugs such as Ozempic or Wegovy, tirzepatide targets two separate hormone receptors simultaneously. This dual mechanism significantly slows gastric emptying the process by which the stomach moves food into the small intestine. While this slowing effect contributes to reduced appetite and weight loss, it also raises the risk of severe and prolonged gastric dysfunction in some patients.
Key Clinical Facts for Attorneys
- Active Ingredient: Tirzepatide (GIP/GLP-1 dual receptor agonist)
- FDA Approval Date: May 13, 2022 (Type 2 diabetes); October 2023 (weight loss, branded as Zepbound)
- Manufacturer: Eli Lilly and Company
- Known GI Risk: Gastric emptying delay, nausea, vomiting, gastroparesis
- Label History: FDA label updates regarding GI risks have been at the center of litigation
Understanding Gastroparesis: The Medical Foundation of These Lawsuits
Gastroparesis is a medical condition in which the stomach muscles stop working properly, slowing or preventing the movement of food from the stomach into the small intestine. In the context of Mounjaro Mounjaro stomach paralysis lawsuits, it is also referred to as stomach paralysis or drug-induced gastroparesis.
For legal professionals, understanding the clinical presentation of gastroparesis is essential for evaluating case merit and building a compelling narrative. Patients who develop this condition after using Mounjaro commonly report:
- Persistent nausea and vomiting, often severe and prolonged
- Early satiety feeling full after eating very little
- Bloating, abdominal pain, and discomfort
- Inability to tolerate solid foods, leading to malnutrition
- Hospitalizations for dehydration and nutritional support
- Worsening blood sugar control in diabetic patients
From a medical records standpoint, gastroparesis is typically confirmed through a gastric emptying study (GES), which measures how quickly food moves through the stomach. Attorneys should look for these diagnostic test results in their clients’ records, as they form a critical piece of the causal chain between Mounjaro use and patient injury.
The Legal Landscape: Mounjaro Stomach Paralysis Lawsuits in 2025
Litigation involving GLP-1 class drugs including Mounjaro, Ozempic, and Wegovy began gaining significant momentum in 2023 and has continued to expand through 2024 and into 2026. While no mounjaro stomach paralysis specific Multi-District Litigation (MDL) has been formally established at the time of this writing, plaintiffs’ attorneys are actively filing cases in multiple federal districts, and consolidation proceedings are being closely watched.
Primary Legal Theories in Mounjaro Lawsuits
Attorneys are pursuing Mounjaro stomach paralysis claims primarily under the following theories:
- Failure to Warn: Plaintiffs allege that Eli Lilly failed to adequately disclose the risk of gastroparesis and severe GI complications in the Mounjaro label and patient-facing materials. Even though the label acknowledges delayed gastric emptying, plaintiffs argue the warnings did not clearly convey the severity or permanence of this risk.
- Negligent Design: Some claims allege that the drug’s dual-agonist mechanism creates an unreasonably dangerous level of GI risk that outweighs its therapeutic benefits for certain patient populations.
- Negligent Misrepresentation: Cases where pharmaceutical sales representatives or promotional materials minimized GI risk to prescribing physicians.
- Medical Negligence: Separate claims against prescribing healthcare providers who failed to screen patients for gastroparesis risk factors or monitor GI symptoms during treatment.
- Breach of Express/Implied Warranty: Arguments that the drug did not perform as represented in clinical trial communications.
What Makes These Cases Challenging to Litigate
Mounjaro stomach paralysis cases present several unique challenges that require strong legal and medical preparation:
- Causation is complex: Many plaintiffs have pre-existing GI conditions, diabetes-related gastric dysfunction, or prior use of other GLP-1 drugs that make it difficult to isolate Mounjaro as the direct cause.
- Medical records are often voluminous: Patients dealing with chronic conditions like Type 2 diabetes typically have years of records that must be systematically reviewed to establish a timeline and causal link.
- Expert testimony is essential: Both on the medical mechanism (how tirzepatide causes gastroparesis) and on the adequacy of the drug’s warning label.
- The label defense is a significant hurdle: Eli Lilly will argue that the FDA-approved label adequately disclosed GI risks, which can limit failure-to-warn claims under federal preemption doctrine.
The Critical Role of Medical Records in Mounjaro Litigation
In any pharmaceutical product liability case, medical records are the backbone of the plaintiff’s case. In Mounjaro stomach paralysis litigation, properly reviewed and organized records serve multiple functions that directly impact case outcomes.
What Attorneys Need to Establish Through Medical Records
| Legal Element | What to Look for in Records |
| Causation | Prescription date, symptom onset timing, gastric emptying study results, GI specialist notes |
| Informed Consent | Signed consent forms, prescriber notes documenting risk discussions, patient education materials provided |
| Pre-existing Conditions | Prior GI diagnoses, diabetic neuropathy history, prior use of Ozempic, Wegovy, or other GLP-1 drugs |
| Damages | Hospitalizations, surgeries (e.g., feeding tube placement), loss of employment records, psychiatric treatment for resulting depression or anxiety |
| Treatment Timeline | Emergency room visits, specialist referrals, medication changes following Mounjaro use, duration of symptoms |
How MedSmith Solutions Supports Your Case Preparation
Reviewing hundreds of pages of medical records manually is time-consuming and increases the risk of missing a critical document. Our team at MedSmith Solutions works alongside attorneys and paralegals to deliver:
- Medical Chronologies: A precise, date-ordered timeline of the client’s medical history, drug use, symptom onset, diagnoses, and treatments built to directly support your legal arguments.
- Narrative Medical Summaries: Narrative-style summaries that translate complex medical terminology into clear, courtroom-ready language that juries and judges can understand.
- Causation Analysis Support: We work with your expert witnesses to identify the medical evidence that links Mounjaro use to the diagnosed gastroparesis.
- Billing Summaries: Organized medical billing records to support your damages calculation and settlement demand letters.
Handling Multiple Mounjaro stomach paralysis?
We Scale With Your Firm
MedSmith Solutions provides dedicated mass tort litigation support for law firms managing high-volume pharmaceutical cases. From intake to trial preparation, our medical review team integrates seamlessly with your legal workflow reducing costs and accelerating case timelines.
Frequently Asked Questions
Is there an active MDL for Mounjaro stomach paralysis cases?
As of 2026, Mounjaro-specific cases are being filed in multiple federal districts. Related GLP-1 drug cases, particularly involving Ozempic and Wegovy, have been consolidated into MDL No. 3094 (Eastern District of Pennsylvania). Mounjaro stomach paralysis cases may be subject to separate or combined proceedings as the litigation develops. Attorneys should monitor the Judicial Panel on Multidistrict Litigation for updates.
What is the statute of limitations for Mounjaro injury claims?
Statutes of limitations vary by state, typically ranging from two to four years from the date of injury or discovery of injury. Because some patients may not link their gastroparesis diagnosis to Mounjaro use immediately, the discovery rule is frequently relevant in these mounjaro stomach paralysis cases.
What types of damages are typically claimed in these lawsuits?
Plaintiffs in Mounjaro stomach paralysis lawsuits typically seek compensation for past and future medical expenses (including hospitalization, specialist care, feeding tube costs), lost wages and diminished earning capacity, pain and suffering, and in cases involving egregious conduct, punitive damages.
Can MedSmith Solutions handle large volumes of records for a law firm managing multiple plaintiffs?
Yes. MedSmith Solutions is structured to support mass tort practices with scalable medical record review capacity. Our team maintains rapid turnaround times even on high-volume cases, ensuring your firm can efficiently evaluate and process multiple plaintiffs in mounjaro stomach paralysis lawsuit without sacrificing accuracy.
Conclusion
Mounjaro stomach paralysis lawsuits represent one of the most significant pharmaceutical litigation opportunities of 2026. Attorneys and law firms that invest in building strong medical evidence foundations anchored by accurate, well-organized medical records will be far better positioned to achieve favorable outcomes for their clients.
The complexity of these cases demands more than a surface-level review of medical histories. It requires a systematic, medically informed approach to record analysis that connects the clinical evidence to the legal theories you are advancing. That is precisely where MedSmith Solutions adds measurable value to your practice.
Whether you are evaluating your first Mounjaro stomach paralysis case or managing a portfolio of clients, our team is ready to support your legal work with the precision and speed your practice demands.
